On 25 July 2025, Nanjing Leads Biolabs Co., Ltd. (9887.HK, Leads Biolabs) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 1.12 billion. CBI is honored to participate in the due diligence work for this IPO Project.

Leads Biolabs is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The company has various drug candidates and has developed multiple proprietary technology platforms, in which six of the drug candidates have successfully progressed into the clinical stage.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management and shareholders with information including litigation, bankruptcy, winding-up and director disqualification records. The due diligence project covered 4 countries and regions, including China, Hong Kong, the United States and Cayman Islands.